Breast cancer

Update on Cancer Therapeutics

Volumn 1, Issue 2, 2006, Pages 187-210

  Popat, Sanjay ^a   Smith, Ian E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Breast cancer; Chemotherapy; Consensus; Endocrine therapy; Neoadjuvant; Prevention; Radiotherapy; Screening; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GEFITINIB; GRANULOCYTE COLONY STIMULATING FACTOR; LETROZOLE; METHOTREXATE; MITOMYCIN C; MOLECULAR MARKER; NAVELBINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE;

ALOPECIA; ANEMIA; ARTHRALGIA; BLEEDING; BONE MARROW SUPPRESSION; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLD SWEAT; CONSENSUS; DIAGNOSTIC IMAGING; DIARRHEA; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FRACTURE; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HEART FAILURE; HORMONAL THERAPY; HORMONE SENSITIVITY; HUMAN; HYPERTENSION; LIBIDO DISORDER; MASTECTOMY; METHODOLOGY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; PARTIAL MASTECTOMY; PERIPHERAL NEUROPATHY; PNEUMONIA; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; SUDDEN DEATH; THROMBOCYTOPENIA; THROMBOEMBOLISM; VAGINA DISCHARGE; VAGINAL DRYNESS;

EID: 33746272237     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.04.003     Document Type: Review

References (157)

1. Langsenlehner U., Krippl P., Renner W., Yazdani-Biuki B., Eder T., Koppel H., et al. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat 90 2 (2005) 113-115
2. Heikkinen K., Rapakko K., Karppinen S.M., Erkko H., Nieminen P., and Winqvist R. Association of common ATM polymorphism with bilateral breast cancer. Int J Cancer (2005)
3. Millikan R.C., Hummer A.J., Wolff M.S., Hishida A., and Begg C.B. HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses. Breast Cancer Res Treat 89 3 (2005) 309-312
4. Benusiglio P.R., Lesueur F., Luccarini C., Conroy D.M., Shah M., Easton D.F., et al. Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res 7 2 (2005) R204-R209
5. Lin W.Y., Chou Y.C., Wu M.H., Huang H.B., Jeng Y.L., Wu C.C., et al. The MTHFR C677T polymorphism, estrogen exposure and breast cancer risk: a nested case-control study in Taiwan. Anticancer Res 24 6 (2004) 3863-3868
6. Lo Y.L., Yu J.C., Chen S.T., Yang H.C., Fann C.S., Mau Y.C., et al. Breast cancer risk associated with genotypic polymorphism of the mitosis-regulating gene Aurora-A/STK15/BTAK. Int J Cancer 115 2 (2005) 276-283
7. Pearce C.L., Hirschhorn J.N., Wu A.H., Burtt N.P., Stram D.O., Young S., et al. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis. J Natl Cancer Inst 97 1 (2005) 51-59
8. Kammerer S., Roth R.B., Reneland R., Marnellos G., Hoyal C.R., Markward N.J., et al. Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res 64 24 (2004) 8906-8910
9. Ahlgren M., Melbye M., Wohlfahrt J., and Sorensen T.I.A. Growth patterns and the risk of breast cancer in women. N Engl J Med 351 16 (2004) 1619-1626
10. Gunnell D., Okasha M., Smith G.D., Oliver S.E., Sandhu J., and Holly J.M. Height, leg length, and cancer risk: a systematic review. Epidemiol Rev 23 2 (2001) 313-342
11. Friedenreich C.M. Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 10 1 (2001) 15-32
12. Collaborative group on hormonal factors in breast cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002;360(9328):187-95.
13. Daling J.R., Malone K.E., Voigt L.F., White E., and Weiss N.S. Risk of breast cancer among young women: relationship to induced abortion. J Natl Cancer Inst 86 21 (1994) 1584-1592
14. Lindefors-Harris B.M., Eklund G., Adami H.O., and Meirik O. Response bias in a case-control study: analysis utilizing comparative data concerning legal abortions from two independent Swedish studies. Am J Epidemiol 134 9 (1991) 1003-1008
15. Jones E.F., and Forrest J.D. Underreporting of abortion in surveys of U.S. women: 1976 to 1988. Demography 29 1 (1992) 113-126
16. Beral V., Bull D., Doll R., Peto R., and Reeves G. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. Lancet 363 9414 (2004) 1007-1016
17. Holmberg L., and Anderson H. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 363 9407 (2004) 453-455
18. MacLennan A., and Sturdee D. The end of WISDOM. Climacteric 5 4 (2002) 313-316
19. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 9382 (2003) 419-427
20. Chlebowski R.T., and Col N. Menopausal hormone therapy after breast cancer. Lancet 363 9407 (2004) 410-411
21. Beatson G. On the treatment of inoperable cases of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 148 (1896) 104-107
22. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 24 (2003) 3243-3253
23. Cavalieri E., Frenkel K., Liehr J.G., Rogan E., and Roy D. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr 27 (2000) 75-93
24. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 18 (1998) 1371-1388
25. Cuzick J., Forbes J., Edwards R., Baum M., Cawthorn S., Coates A., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 9336 (2002) 817-824
26. Martino S., Cauley J.A., Barrett-Connor E., Powles T.J., Mershon J., Disch D., et al. Continuing outcomes relevant to evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96 23 (2004) 1751-1761
27. Cummings S.R., Eckert S., Krueger K.A., Grady D., Powles T.J., Cauley J.A., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281 23 (1999) 2189-2197
28. Cauley J.A., Norton L., Lippman M.E., Eckert S., Krueger K.A., Purdie D.W., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65 2 (2001) 125-134
29. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 9324 (2002) 2131-2139
30. Cuzick J. Aromatase inhibitors in prevention-data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163 (2003) 96-103
31. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 19 (2003) 1793-1802
32. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 11 (2004) 1081-1092
33. Easton D.F., Narod S.A., Ford D., and Steel M. The genetic epidemiology of BRCA1. Breast cancer linkage consortium. Lancet 344 8924 (1994) 761
34. Struewing J.P., Hartge P., Wacholder S., Baker S.M., Berlin M., McAdams M., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336 20 (1997) 1401-1408
35. Calderon-Margalit R., and Paltiel O. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer 112 3 (2004) 357-364
36. Hartmann L.C., Sellers T.A., Schaid D.J., Frank T.S., Soderberg C.L., Sitta D.L., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93 21 (2001) 1633-1637
37. Hartmann L.C., Schaid D.J., Woods J.E., Crotty T.P., Myers J.L., Arnold P.G., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340 2 (1999) 77-84
38. Meijers-Heijboer H., van Geel B., van Putten W.L., Henzen-Logmans S.C., Seynaeve C., Menke-Pluymers M.B., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345 3 (2001) 159-164
39. Rebbeck T.R., Friebel T., Lynch H.T., Neuhausen S.L., van't Veer L., Garber J.E., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22 6 (2004) 1055-1062
40. Ghosh K., and Hartmann L.C. Current status of prophylactic mastectomy. Oncology (Huntington) 16 10 (2002) 1319-1325
41. Contant C.M., Menke-Pluijmers M.B., Seynaeve C., Meijers-Heijboer E.J., Klijn J.G., Verhoog L.C., et al. Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation. Eur J Surg Oncol 28 6 (2002) 627-632
42. Nystrom L., Andersson I., Bjurstam N., Frisell J., Nordenskjold B., and Rutqvist L.E. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359 9310 (2002) 909-919
43. de Koning H.J., Boer R., Warmerdam P.G., Beemsterboer P.M., and van der Maas P.J. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst 87 16 (1995) 1217-1223
44. Elmore J.G., Barton M.B., Moceri V.M., Polk S., Arena P.J., and Fletcher S.W. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 338 16 (1998) 1089-1096
45. Mandelson M.T., Oestreicher N., Porter P.L., White D., Finder C.A., Taplin S.H., et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 92 13 (2000) 1081-1087
46. Kriege M., Brekelmans C.T.M., Boetes C., Besnard P.E., Zonderland H.M., Obdeijn I.M., et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351 5 (2004) 427-437
47. Claus E.B., Risch N., and Thompson W.D. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73 3 (1994) 643-651
48. Humphrey L.L., Helfand M., Chan B.K., and Woolf S.H. Breast cancer screening: a summary of the evidence for the U.S. Preventive services task force. Ann Intern Med 137 5, Part 1 (2002) 347-360
49. Smith R.A., Cokkinides V., and Eyre H.J. American cancer society guidelines for the early detection of cancer. CA Cancer J Clin 55 1 (2005) 31-44
50. Wald N.J., Chamberlain J., and Hackshaw A. European society of mastology consensus conference on breast cancer screening: report of the evaluation committee. Br J Radiol 67 802 (1994) 925-933
51. Ballard-Barbash R., Klabunde C., Paci E., Broeders M., Coleman E.A., Fracheboud J., et al. Breast cancer screening in 21 countries: delivery of services, notification of results and outcomes ascertainment. Eur J Cancer Prev 8 5 (1999) 417-426
52. White E., Miglioretti D.L., Yankaskas B.C., Geller B.M., Rosenberg R.D., Kerlikowske K., et al. Biennial versus annual mammography and the risk of late-stage breast cancer. J Natl Cancer Inst 96 24 (2004) 1832-1839
53. Elmore J.G., Wells C.K., Lee C.H., Howard D.H., and Feinstein A.R. Variability in radiologists' interpretations of mammograms. N Engl J Med 331 22 (1994) 1493-1499
54. Doi K., Giger M.L., Nishikawa R.M., Hoffmann K.R., MacMahon H., and Schmidt R.A. Potential usefulness of digital imaging in clinical diagnostic radiology: computer-aided diagnosis. J Digit Imaging 8 1 Suppl. 1 (1995) 2-7
55. Warren Burhenne L.J., Wood S.A., D'Orsi C.J., Feig S.A., Kopans D.B., O'Shaughnessy K.F., et al. Potential contribution of computer-aided detection to the sensitivity of screening mammography. Radiology 215 2 (2000) 554-562
56. Gur D., Sumkin J.H., Rockette H.E., Ganott M., Hakim C., Hardesty L., et al. Changes in breast cancer detection and mammography recall rates after the introduction of a computer-aided detection system. J Natl Cancer Inst 96 3 (2004) 185-190
57. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 6871 (2002) 530-536
58. Ayers M., Symmans W.F., Stec J., Damokosh A.I., Clark E., Hess K., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22 12 (2004) 2284-2293
59. Bertucci F., Finetti P., Rougemont J., Charafe-Jauffret E., Nasser V., Loriod B., et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 64 23 (2004) 8558-8565
60. Iwao-Koizumi K., Matoba R., Ueno N., Kim S.J., Ando A., Miyoshi Y., et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23 3 (2005) 422-431
61. Jansen M.P.H.M., Foekens J.A., van Staveren I.L., Dirkzwager-Kiel M.M., Ritstier K., Look M.P., et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23 4 (2005) 732-740
62. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 9460 (2005) 671-679
63. Jenssen T.K., and Hovig E. Gene-expression profiling in breast cancer. Lancet 365 9460 (2005) 634-635
64. Michiels S., Koscielny S., and Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365 9458 (2005) 488-492
65. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 27 (2004) 2817-2826
66. Paik S., Shak S., Tang G., et al. Multi-gene RT-PCR assay for predicting recurrence in node negative brreast cancer patients-NSABP studies B-20 and B-14. Breast Cancer Res Treat 82 (2003) A16
67. Cobleigh M.A., Bitterman P., Baker J., et al. Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer pateints with 10 or more positive lymph nodes: high throughput RT-PCR assay of paraffin-embedded tissue. Proc Am Soc Clin Oncol 22 (2003) 850
68. Esteban J., Baker J., Cronin M., et al. Tumor gene expression and prognosis in breast cancer: a multi-gene RT-PCR assay of paraffin-embedded tissue. Proc Am Soc Clin Oncol 22 (2003) 850
69. Esteva F.J., Sahin A.A., Coombes K., et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients - M.D. Anderson clinical validation study. Breast Cancer Res Treat 82 Suppl. 1 (2003) S11
70. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 25 (2002) 1999-2009
71. Piccart MJ, Loi S, vant't Veer L, Saghatchian-d'Assignies M, Glass A, Ellis P, et al. Multi-center external validation of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: are the results still outperforming the clinical-pathological criteria? http://www.abstracts2view.com/sabcs/view.php?nu=BCS4L_1058.
72. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351 8 (2004) 781-791
73. Cristofanilli M., Hayes D.F., Budd G.T., Ellis M.J., Stopeck A., Reuben J.M., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23 7 (2005) 1420-1430
74. Hayes D.F., Cristofanilli M., Budd G.T., Ellis M., Stopeck A., Matera J., et al. Monitoring circulating tumor cell (CTC) levels to predict progression in metastatic breast cancer (MBC): a prospective, multi-institutional trial. J Clin Oncol 22 14S (2004) 509
75. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96 12 (2004) 926-935
76. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 21 (2004) 2129-2139
77. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 5676 (2004) 1497-1500
78. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 2 (2004) 117-127
79. Pandolfi P.P. Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med 351 22 (2004) 2337-2338
80. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. J Clin Oncol 22 14S (2004) 847
81. Whelan T., Goss P.E., Ingle J., Pater J.L., Shepherd L.E., Palmer M., et al. Assessment of quality of life (QOL) in MA.17, a randomizes placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. J Clin Oncol 22 14S (2004) 517
82. Coombes R.C., Hall E., Snowdon C.F., and Bliss J.M. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. Breast Cancer Res Treat 88 Suppl. 1 (2004) S7
83. Coleman R.E., Banks L.M., Hall E., Price D., Girgis S., Bliss J.M., et al. Intergroup Exemestane Study: 1 year results of the bone sub-protocol. Breast Cancer Res Treat 88 Suppl. 1 (2004) S35
84. Bertelli G., Hall E., Bliss J.M., Snowdon C.F., and Coombes R.C. Intergroup Exemestane Study: results of the endometrial sub-protocol. Breast Cancer Res Treat 88 Suppl. 1 (2004) S35
85. Fallowfield L., Price M.H., Hall E., Coombes R.C., and Bliss J.M. Intergroup Exemestane Study: results of the quality of life sub-protocol. Breast Cancer Res Treat 88 Suppl. 1 (2004) S8
86. Jakesz R., Kaufmann M., Gnant M., Jonat W., Mittlboeck M., Greil R., et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results form 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 88 Suppl. 1 (2004) S7
87. Fallowfield L., Cella D., Cuzick J., Francis S., Locker G., and Howell A. Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 22 21 (2004) 4261-4271
88. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 9453 (2005) 60-62
89. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351(9114):1451-67.
90. BIG 1-98 Collaborative Group. Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women in receptor-positive breast cancer. BIG 1-98: a prospective randomized double-blind phase III study. Breast 14 Suppl. 1 (2005) S3
91. Winer E.P., Hudis C., Burstein H.J., Wolff A.C., Pritchard K.I., Ingle J.N., et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol 23 3 (2005) 619-629
92. Harris E.E.R., Christensen V.J., Hwang W.T., Fox K., and Solin L.J. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 23 1 (2005) 11-16
93. Ahn P.H., Vu H.T., Lannin D., Obedian E., DiGiovanna M.P., Burtness B., et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 23 1 (2005) 17-23
94. Pierce L.J., Hutchins L.F., Green S.R., Lew D.L., Gralow J.R., Livingston R.B., et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol 23 1 (2005) 24-29
95. Eiermann W., Paepke S., Appfelstaedt J., Llombart-Cussac A., Eremin J., Vinholes J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12 11 (2001) 1527-1532
96. Smith I.E., Dowsett M., Ebbs S.R., Dixon J.M., Skene A., Blohmer J.-U., et al. Neoadjuvant treatment of postmenapausal breast cancer with anastrozole, tamoxifen or both in combination: the impact multicentre double-blind randomised trial. J Clin Oncol. 23 22 (2005) 5108-5116
97. Dowsett M., Ebbs S.R., Dixon J.M., Skene A., Griffith C., Boeddinghaus I., et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists. J Clin Oncol 23 11 (2005) 2477-2492
98. Semiglazov V.F., Semiglazov V., Ivanov V., Bozhok A., Ziltsova E., Paltuev R., et al. The relative efficacy of neoadjuvant endocrine therapy vs. chemotherapy in postmenopausal women with ER-positive breast cancer. J Clin Oncol 22 14S (2004) 519
99. Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cussac A., Janicke F., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 18 (2001) 3808-3816
100. Citron M.L., Berry D.A., Cirrincione C., Hudis C., Winer E.P., Gradishar W.J., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol 21 8 (2003) 1431-1439
101. Mobus V.J., Untch M., Du Bois A., Lueck H.-J., Thomssen C., Kuhn W., et al. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (≥4 + LN). First results of an AGO-trial. J Clin Oncol 22 14S (2004) 513
102. Comella G., D'Aiuto, Comella P., Thomas R., Capasso I., Silvestro P., et al. Comparison of weekly cisplatin-epirubicin-paclitaxel (PET) with triweekly epirubicin-paclitaxel (ET) in locally advanced breast cancer (LABC). SICOG 9908 phase III trial. J Clin Oncol 22 14S (2004) 511
103. Buzdar A.U., Hunt K., Smith T., Francis D., Ewer M., Booser D., et al. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with tastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results if a randomized trial in operable breast cancer (BC) with HER/2 positive disease. J Clin Oncol 22 14S (2004) 520
104. Vogel C.L., Wojtukiewicz M.Z., Carroll R.R., Tjulandin S.A., Barajas-Figueroa L.J., Wiens B.L., et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23 6 (2005) 1178-1184
105. Henderson I.C., Berry D.A., Demetri G.D., Cirrincione C.T., Goldstein L.J., Martino S., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21 6 (2003) 976-983
106. Bear H.D., Anderson S., Brown A., Smith R., Mamounas E.P., Fisher B., et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 21 22 (2003) 4165-4174
107. Roche H., Fumoleau P., Spielmann R., Canon J.L., Delozier T., Kerbrat P., et al. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs. 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer. Breast Cancer Res Treat 88 Suppl. 1 (2004) S16
108. Taghian A.G., Assaad S.I., Niemierko A., Kuter I., Younger J., Schoenthaler R., et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 93 23 (2001) 1806-1811
109. Pansegrau G.K., and Gelmon K.A. Lymph-node-negative oestrogen-receptor-positive breast cancer. Lancet 364 9437 (2004) 820-821
110. Fisher B., Jeong J.H., Bryant J., Anderson S., Dignam J., Fisher E.R., et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364 9437 (2004) 858-868
111. Fisher B., Jeong J.H., Anderson S., and Wolmark N. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from national surgical adjuvant breast and bowel project clinical trials. J Natl Cancer Inst 96 24 (2004) 1823-1831
112. Albain K.S. Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials. J Natl Cancer Inst 96 24 (2004) 1801-1804
113. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352(9132):930-42.
114. French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of french adjuvant study group 05 randomized trial. J Clin Oncol 2001;19(3):602-11.
115. Bonneterre J., Roche H., Kerbrat P., Bremond A., Fumoleau P., Namer M., et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the french adjuvant study group 05 randomized trial. J Clin Oncol 23 12 (2005) 2686-2693
116. Bonneterre J., Roche H., Kerbrat P., Fumoleau P., Goudier M.J., Fargeot P., et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French Adjuvant Study Group. J Clin Oncol 22 15 (2004) 3070-3079
117. Fargeot P., Bonneterre J., Roche H., Lortholary A., Campone M., Van Praagh I., et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French Adjuvant Study Group 08 trial. J Clin Oncol 22 23 (2004) 4674-4682
118. Schott A., and Hayes D.F. Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem. J Clin Oncol 22 23 (2004) 4660-4662
119. Fisher B., Anderson S., Bryant J., Margolese R.G., Deutsch M., Fisher E.R., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 16 (2002) 1233-1241
120. Fyles A.W., McCready D.R., Manchul L.A., Trudeau M.E., Merante P., Pintilie M., et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 351 10 (2004) 963-970
121. Hughes K.S., Schnaper L.A., Berry D., Cirrincione C., McCormick B., Shank B., et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 351 10 (2004) 971-977
122. Smith I.E., and Ross G.M. Breast radiotherapy after lumpectomy-no longer always necessary. N Engl J Med 351 10 (2004) 1021-1023
123. Vinh-Hung V., and Verschraegen C. Breast-conserving surgery with or without radiotherapy: pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst 96 2 (2004) 115-121
124. Piedbois P., and Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol (2004)
125. Vallis K.A., and Tannock I.F. Postoperative radiotherapy for breast cancer: growing evidence for an impact on survival. J Natl Cancer Inst 96 2 (2004) 88-89
126. Ragaz J., Olivotto I.A., Spinelli J.J., Phillips N., Jackson S.M., Wilson K., et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia Randomized Trial. J Natl Cancer Inst 97 2 (2005) 116-126
127. Ragaz J., Jackson S.M., Le N., Plenderleith I.H., Spinelli J.J., Basco V.E., et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337 14 (1997) 956-962
128. Taghian A., Jeong J.H., Mamounas E., Anderson S., Bryant J., Deutsch M., et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol 22 21 (2004) 4247-4254
129. Olivotto I.A., Truong P.T., and Chua B. Postmastectomy radiation therapy: who needs it?. J Clin Oncol 22 21 (2004) 4237-4239
130. Whelan T., and Levine M. More evidence that locoregional radiation therapy improves survival: what should we do?. J Natl Cancer Inst 97 2 (2005) 82-84
131. Hojris I., Overgaard M., Christensen J.J., and Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet 354 9188 (1999) 1425-1430
132. Smith R.E., Bryant J., DeCillis A., and Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21 7 (2003) 1195-1204
133. Keller A.M., Mennel R.G., Georgoulias V.A., Nabholtz J.M., Erazo A., Lluch A., et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin c plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22 19 (2004) 3893-3901
134. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
135. Cobleigh M.A., Langmuir V.K., Sledge G.W., Miller K.D., Haney L., Novotny W.F., et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30 5, Suppl. 16 (2003) 117-124
136. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 4 (2005) 792-799
137. Winer E.P., Berry D.A., Woolf S., Duggan D., Kornblith A., Harris L.N., et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22 11 (2004) 2061-2068
138. Seidman A.D., Berry D., Cirrincone L., Harris L., Dressler L., Muss M., et al. CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 22 14S (2004) 512
139. Albain K.S., Nag S., Calderillo-Ruiz G., Jordaan J.P., Llombart A., Pluzanska A., et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol 22 14S (2004) 510
140. O'Shaughnessy J., Nag S., Calderillo-Ruiz G., Jordaan J.P., Llombart A., Pluzanska A., et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Interim results of a global phase III study. Proc Am Soc Clin Oncol 22 (2003) 7
141. Zielinski C., Beslija S., Mrsic-Krmpotic Z., Welnicka-Jaskiewicz M., Wiltschke C., Kahan Z., et al. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a central european cooperative oncology group international, multicenter, prospective, randomized phase III trial. J Clin Oncol 23 7 (2005) 1401-1408
142. Conte P.F., Gennari A., Donati S., Salvadori B., Baldini E., Bengala C., et al. Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat 68 2 (2001) 171-179
143. Seidman A.D. Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism?. J Clin Oncol 21 4 (2003) 577-579
144. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 9 (1999) 2639-2648
145. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
146. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 3 (2002) 719-726
147. Tripathy D., Slamon D.J., Cobleigh M., Arnold A., Saleh M., Mortimer J.E., et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22 6 (2004) 1063-1070
148. Tedesco K.L., Thor A.D., Johnson D.H., Shyr Y., Blum K.A., Goldstein L.J., et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 22 6 (2004) 1071-1077
149. Esteva F.J., Valero V., Booser D., Guerra L.T., Murray J.L., Pusztai L., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20 7 (2002) 1800-1808
150. Meden H., Beneke A., Hesse T., Novophashenny I., and Wischnewsky M. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study. Anticancer Res 21 2B (2001) 1301-1305
151. Pegram M.D., Pienkowski T., Northfelt D.W., Eiermann W., Patel R., Fumoleau P., et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96 10 (2004) 759-769
152. Allred D.C., Clark G.M., Tandon A.K., Molina R., Tormey D.C., Osborne C.K., et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10 4 (1992) 599-605
153. Paik S., Bryant J., Park C., Fisher B., Tan-Chiu E., Hyams D., et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90 18 (1998) 1361-1370
154. Konecny G.E., Thomssen C., Luck H.J., Untch M., Wang H.J., Kuhn W., et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 96 15 (2004) 1141-1151
155. Howell A., Robertson J.F.R., Abram P., Lichinitser M.R., Elledge R., Bajetta E., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22 9 (2004) 1605-1613
156. Howell A., Robertson J.F.R., Quaresma Albano J., Aschermannova A., Mauriac L., Kleeberg U.R., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20 16 (2002) 3396-3403
157. Nabholtz J.M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a north american multicenter randomized trial. J Clin Oncol 18 22 (2000) 3758-3767